Cited 2 times in
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신상준 | - |
dc.date.accessioned | 2024-03-22T06:13:49Z | - |
dc.date.available | 2024-03-22T06:13:49Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198465 | - |
dc.description.abstract | Background: Although introduction of immune checkpoint inhibitors has revolutionized the treatment of cancer, their response rates are generally low. Preclinical and early phase clinical data suggest that MEK inhibition may sensitize tumors to immune checkpoint inhibitors by upregulating tumor antigen expression, programmed death-ligand 1 (PD-L1) expression, and tumor T-cell infiltration. We evaluated the efficacy and safety of cobimetinib plus atezolizumab in patients with advanced solid tumors in the open-label, multicohort phase II COTEST study. Patients and methods: This analysis of the COTEST trial included patients from cohorts 1-4 [1-3: anti-programmed cell death protein 1 (PD-1)/PD-L1 treatment-naive patients; 4: patients with disease progression on anti-PD-1/anti-PD-L1 treatment] who received cobimetinib 60 mg once daily for the first 21 days and intravenous infusions of atezolizumab 840 mg on days 1 and 15 of each 28-day cycle. Efficacy endpoints included objective response rate, overall survival, progression-free survival (PFS), and disease control rate. Results: Overall, 77 patients were enrolled in cohorts 1-4 (78% male; median age 62.8 years). Objective response rate was 20% in cohort 1 [squamous cell carcinoma of the head and neck (SCCHN)], 30% in cohort 2 (urothelial carcinoma), and 18% in cohort 3 (renal cell carcinoma); there were no responders among 20 patients in cohort 4 (SCCHN). The disease control rates in cohorts 1-4 were 50%, 40%, 24%, and 25%, respectively. The median PFS was 5.5, 3.4, 3.4, and 3.6 months in cohorts 1-4, respectively, and the median overall survival was 16.8, 18.7, 21.7, and 7.7 months, respectively. Most adverse events were of grade 1/2 and were manageable. Conclusions: Cobimetinib plus atezolizumab had moderate activity in patients with anti-PD-1/PD-L1 treatment-naive SCCHN and urothelial carcinoma, and weak activity in anti-PD-1/PD-L1 treatment-naive renal cell carcinoma, and no activity in checkpoint inhibitor-treated patients. © 2023 The Authors | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BMJ | - |
dc.relation.isPartOf | ESMO OPEN | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Carcinoma, Renal Cell* | - |
dc.subject.MESH | Carcinoma, Transitional Cell* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immune Checkpoint Inhibitors | - |
dc.subject.MESH | Kidney Neoplasms* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Urinary Bladder Neoplasms* | - |
dc.title | Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | E Sherman | - |
dc.contributor.googleauthor | J L Lee | - |
dc.contributor.googleauthor | P R Debruyne | - |
dc.contributor.googleauthor | B Keam | - |
dc.contributor.googleauthor | S J Shin | - |
dc.contributor.googleauthor | A Gramza | - |
dc.contributor.googleauthor | I Caro | - |
dc.contributor.googleauthor | R Amin | - |
dc.contributor.googleauthor | K Shah | - |
dc.contributor.googleauthor | Y Yan | - |
dc.contributor.googleauthor | R Huddart | - |
dc.contributor.googleauthor | T Powles | - |
dc.identifier.doi | 10.1016/j.esmoop.2023.100877 | - |
dc.contributor.localId | A02105 | - |
dc.relation.journalcode | J03799 | - |
dc.identifier.eissn | 2059-7029 | - |
dc.identifier.pmid | 36947985 | - |
dc.subject.keyword | COTEST | - |
dc.subject.keyword | atezolizumab | - |
dc.subject.keyword | cobimetinib | - |
dc.subject.keyword | phase II trial | - |
dc.subject.keyword | solid tumors | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | 신상준 | - |
dc.citation.volume | 8 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 100877 | - |
dc.identifier.bibliographicCitation | ESMO OPEN, Vol.8(2) : 100877, 2023-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.